» Articles » PMID: 29724086

The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn's Disease

Overview
Journal Gut Liver
Specialty Gastroenterology
Date 2018 May 5
PMID 29724086
Citations 1
Authors
Affiliations
Soon will be listed here.
Citing Articles

Trajectory of body mass index and obesity in children with Crohn's disease compared to healthy children.

Mitchel E, Huang J, Zemel B, Baldassano R, Albenberg L, Denburg M J Pediatr Gastroenterol Nutr. 2024; 78(1):85-94.

PMID: 38291691 PMC: 11823676. DOI: 10.1002/jpn3.12063.


Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.

Choi Y, Kim T, Park D, Chung J, Kim K, Kwon K Int J Colorectal Dis. 2019; 34(10):1713-1721.

PMID: 31471699 DOI: 10.1007/s00384-019-03368-1.

References
1.
Griffin L, Thayu M, Baldassano R, DeBoer M, Zemel B, Denburg M . Improvements in Bone Density and Structure during Anti-TNF-α Therapy in Pediatric Crohn's Disease. J Clin Endocrinol Metab. 2015; 100(7):2630-9. PMC: 4490303. DOI: 10.1210/jc.2014-4152. View

2.
Hyams J, Walters T, Crandall W, Kugathasan S, Griffiths A, Blank M . Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011; 27(3):651-62. DOI: 10.1185/03007995.2010.547575. View

3.
Lee E, Moon J, Ko J, Yang H, Jang J, Kim J . Effect of the Baseline Vitamin D Level on Growth Outcome in Pediatric Crohn Disease. Pediatr Gastroenterol Hepatol Nutr. 2017; 20(1):41-46. PMC: 5385306. DOI: 10.5223/pghn.2017.20.1.41. View

4.
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132(3):863-73. DOI: 10.1053/j.gastro.2006.12.003. View

5.
Cameron F, Altowati M, Rogers P, McGrogan P, Anderson N, Bisset W . Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2016; 64(1):47-55. DOI: 10.1097/MPG.0000000000001379. View